The Long-Term Outcomes of Surgery Versus Endoscopic Treatment in Patients With Siewert Type II T1M0N0 Adenocarcinoma of the Esophagogastric Junction

Han Chen1,2†, Xin Yu†1,2, Ruoyun Yang1,2, Shuo Li1,2, Guoxin Zhang1,2, Xinmin Si1,2, and Xiaoying Zhou1,2

Abstract
Objective: We compared the long-term prognosis of surgery and endoscopic treatment (ET) in patients diagnosed with Siewert Type II pT1N0M0 adenocarcinoma of the esophagogastric junction (AEG).

Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, we performed a real-world retrospective cohort study and enrolled patients with Siewert Type II pT1N0M0 AEG who underwent surgery or endoscopic treatment (ET) from 2010 to 2018. Matched cohorts were generated using propensity score matching. Competing-risk analysis was applied. The cumulative incidence function was used to calculate cancer-specific death and other causes of death (OCD) at different time points. Univariate and multivariate analyses were performed to identify significant prognostic factors by using the subdistribution hazard ratio.

Results: We enrolled 725 patients: 462 underwent surgery and 263 received ET. The 5 year cumulative CSD incidence significantly differed between surgery and ET cohorts (16.87% vs 11.08%, P = .01). Following PSM, 2 balanced groups (n = 219 patients each) were analyzed. No significant difference in the 5 year cumulative incidences of CSD was noted between cohorts (17.61% vs. 12.16%, P = .14). In multivariable analysis, the CSD incidence was high among patients with aged ≥65 (SHR 2.29, 95% CI 0.99-5.33, P = .05) and T1b-stage (SHR 1.92, 95% CI 1.03-3.57, P = .04); treatment (surgery or ET) was not significantly associated with cancer survival (SHR 1.51, 95% CI 0.81-2.81, P = .20).

Conclusion: Long-term survival did not significantly differ among patients with Siewert Type II pT1N0M0 AEG adenocarcinoma undergoing surgery or ET. ET may be considered in patients >65 years old or those with submucosal (T1b-stage) cancer of AEG.

Keywords
superficial adenocarcinoma of the esophagogastric junction, siewert type II, long-term survival outcome, competing-risk analysis, early stage, propensity score matching
Introduction

Over the last few decades, there has been a sharp increase in the incidence of adenocarcinoma of the esophagogastric junction (AEG) in Western countries.\(^1,2\) This growing incidence may be associated with 2 main risk factors: obesity and gastroesophageal reflux disease, both more common in non-Asian countries.\(^3\) The esophagogastric junction (EGJ), the meeting point of the esophageal squamous epithelium and gastric columnar mucosa, forms the demarcation line of the stomach and esophagus.\(^4\) Given the anatomical location, the classification of AEG and optimal treatment strategies remain controversial.

Clinically, the Siewert classification is the most widely accepted classification of EGJ adenocarcinoma, categorized as follows: Siewert I (lower esophageal cancer, the epicenter within 1-5 cm above the EGJ), Siewert II (true cardia cancer, the center within +1 to −2 cm of the EGJ), and Siewert III (subcardial cancer, the epicenter within 2-5 cm below the EGJ).\(^5\) However, this schema has not yet been universally employed. The Surveillance, Epidemiology, and End Results (SEER) database utilizes the International Classification of Diseases for Oncology, third edition (ICD-O-3) topography classification. In this system, tumors of the gastric cardia are identified by the “C16.0 Cardia” of ICD-O-3, which can be categorized as the Siewert II EGJ cancers (true cardia cancer).\(^6,7\)

Considering the 3 AEG subtypes, it has been reported that the incidence of Siewert II AEG has dramatically increased by approximately 2-fold in recent decades.\(^8\) However, no consensus has been reached regarding the optimal treatment of Siewert II AEG, particularly regarding the optimal treatment approaches, the extent of lymph node dissection, or reconstruction methods.\(^9\) With the help of advances in endoscopic technology, EGJ tumors can be detected at an early stage. Considering patients with T1-stage superficial Siewert II AEG, endoscopic treatment (ET) has been developed as a minimally invasive alternative, although surgical resection remains the traditional option. Several authoritative guidelines recommend ET and surgery as 2 major treatment options for Siewert II AEG with T1a and T1b stage.\(^10−12\) Compared with surgery approaches, endoscopic therapies allow the preservation of gastric cardia and have been associated with a reduction in postoperative morbidity and mortality.\(^13,14\) Accordingly, both treatment strategies can be considered for patients with superficial Siewert II AEG.

Several studies have reported the comparable short- or long-term efficacies of surgery and ET in patients with AEG; however, these findings mostly pertained to Asian populations.\(^15−17\) Compared with these studies focusing on Asia populations, few studies specifically compared the long-term survival among Western populations. Furthermore, no independent analyses are available to compare differences in survival between surgery and ET, particularly for T1-stage AEG, limited to mucosa and submucosa. Therefore, to the best of our knowledge, the present study was the first to compare

the long-term prognosis between surgery and ET in patients with Siewert Type II pT1N0M0 AEG using the national SEER data among the United States population.

Methods

This study was conducted in accordance with the Declaration of Helsinki. Institutional review board approval and informed consent were not required in the current study because SEER research data are publicly available and all patients data are de-identified.

Herein, we collected population-based data using the SEER program. The SEER database named “SEER research Plus Data, 18 registries, Nov 2020 sub (2000-2018)” was searched by using the SEER*Stat program version 8.3.9. The topography code C16.0 (ICD-O-3) was used to primarily identify qualified patients with Siewert Type II EGJ cancer.

Inclusion Criteria Were as Follows

(1) Siewert Type II EGJ cancer (the true gastric cardia cancer); (2) pT1N0M0 stage carcinoma (no tumor invasion beyond the submucosa); (3) histopathological diagnosis of adenocarcinoma on post-treatment specimens, including the ICD-O-3 codes: 8140-8389 for adenocarcinoma; (4) surgical resection or ET without additional adjuvant therapies. Exclusion criteria were as follows: (1) histopathological diagnosis of other types of carcinoma (such as squamous cell carcinoma, neuroendocrine tumor, gastric stromal tumor, lymphoma, and other specific or mixed types); (2) tumor with the undefined pathological origin and metastatic cancer; (3) age <18 years; (4) adjuvant therapies such as radiotherapy or chemotherapy before or after the primary treatment; (5) T2/T3/T4 stage with positive lymph node metastasis; (6) tumor diagnosis was solely on autopsy or based on the death certificate; (7) missed follow-up (survival at 0 months). The eighth TNM staging system of the American Joint Committee on Cancer (AJCC) was applied to enroll the largest possible number of patients.\(^18\)

The tumor stage was categorized as I, II, and III according to the post-treatment pathological status. The invasion depth was classified as mucosal (T1a), submucosal (T1b). The tumor size was categorized as <3 cm and ≥3 cm. Histologic grade was categorized as well-differentiated, moderately differentiated, poorly differentiated, and undifferentiated type. Based on the surgery code for the stomach in the SEER program coding and staging manual: surgery included the following subgroups: partial or subtotal gastrectomy; near-total or total gastrectomy; ET including both excisions (polypectomy, excisional biopsy, laser excision) and local tumor destruction (photodynamic therapy, cryosurgery, laser). The survival time was defined as the duration from the date of diagnosis to the death or the last follow-up. The baseline and clinicopathologic characteristics (age at diagnosis, sex, race, year of diagnosis, tumor size, stage, histology and grade), cancer incidence, treatment strategies (surgery or ET), and survival-related information
Survival months, status, cancer-specific death (CSD), and other causes of death (OCD) were collected accordingly.

**Statistical Analysis**

Statistical analysis was performed using SPSS Statistics for Windows, Version 25.0 (IBM Corporation, Armonk, NY), and roentgen software (version 4.1.0). Pearson chi-square test or Fisher’s exact tests were applied to compare categorical variables. The propensity score matching (PSM) algorithm was used to generate matched cohorts by controlling confounding bias. The match ratio of patients in both surgery and ET groups was 1:1, with a .01 of match tolerance. The sample size calculation was performed considering log-rank analysis accounting for competing risks in PASS 15 version, based on the following parameters: $\alpha = .05$ (2-sided); power: $1-\beta = .8$; event of interest rate in ET group, $F_{E1} = .15$ and event rate in surgery group, $F_{E2} = .10$; competing risks rate in the ET group, $F_{C1} = .17$ and $F_{C2}$...

**Figure 1.** Flowchart of generating the study groups.
competing risks rate in the surgery group, Fcr2 = .12. The resulting total sample size was 201 for each group.

The primary outcomes were CSD and OCD in each group at different time points. Competing-risk regression analysis was applied using the ‘survival’ and ‘cmprsk’ packages in R. The cumulative incidence function (CIF) was used to calculate the incidence of CSDs and OCDs at the 1-, 3-, and 5-year time points. The CIF differences between surgery and ET groups

### Table 1. Baseline Characteristics of Patients.

| Variables                  | Unmatched Cohort | Matched Cohort |
|----------------------------|------------------|----------------|
|                            | Er, n = 263      | Surgery, n = 462 | Er, n = 219      | Surgery, n = 219 |
|                            | N (%)            | N (%)           | N (%)            | N (%)           |
| Age at diagnosis (years)   | <.01*            | .92            |
| <65                        | 73 (27.8)        | 180 (39.0)      | 68 (31.1)        | 67 (30.6)       |
| ≥65                        | 190 (72.2)       | 282 (61.0)      | 151 (68.9)       | 152 (69.4)      |
| Sex                        | .27              | .63            |
| Female                     | 67 (25.5)        | 101 (21.9)      | 44 (20.1)        | 40 (18.3)       |
| Male                       | 196 (74.5)       | 361 (78.1)      | 175 (79.9)       | 179 (81.7)      |
| Race                       | .80              | .66            |
| Non-hispanic               | 245 (93.2)       | 428 (92.6)      | 209 (95.4)       | 207 (94.5)      |
| Hispanic                   | 18 (6.8)         | 34 (7.4)        | 10 (4.6)         | 12 (5.5)        |
| Tumor size (cm)            | <.01*            | .45            |
| <3                         | 249 (94.7)       | 386 (83.5)      | 206 (94.1)       | 202 (92.2)      |
| ≥3                         | 14 (5.3)         | 76 (16.5)       | 13 (5.9)         | 17 (7.8)        |
| Histology grade            | <.01*            | .82            |
| Well                       | 77 (29.3)        | 95 (20.6)       | 55 (25.1)        | 63 (28.8)       |
| Moderately                 | 141 (53.6)       | 242 (52.4)      | 121 (55.3)       | 114 (52.1)      |
| Poorly                     | 40 (15.2)        | 120 (26.0)      | 40 (18.3)        | 38 (17.4)       |
| Undifferentiated           | 5 (1.9)          | 5 (1.1)         | 3 (1.4)          | 4 (1.8)         |
| Histology type             | <.01*            | .97            |
| Intestinal                 | 11 (4.2)         | 47 (10.2)       | 10 (4.5)         | 9 (4.1)         |
| Diffused                   | 1 (4.4)          | 5 (1.1)         | 1 (.5)           | 1 (.5)          |
| Unclassified               | 251 (95.4)       | 410 (88.7)      | 208 (95.0)       | 209 (95.4)      |
| T Stage                    | <.01*            | .92            |
| T1a                        | 185 (70.3)       | 178 (38.5)      | 141 (64.4)       | 142 (64.8)      |
| T1b                        | 78 (29.7)        | 284 (61.5)      | 78 (35.6)        | 77 (35.2)       |

Note: Each P value was derived from the Chi-square or Fisher’s exact analyses between the single variables in ET or surgery groups. *statistical significance was considered as P ≤ .05.
Table 2. Survival Data of CSD and NCD in this Study.

| Cohort          | Cumulative Incidence of Death(%) | Cancer-Specific | Other Causes | Cancer-Specific | Other Causes | Cancer-Specific | Other Causes | Cancer-Specific | Other Causes |
|-----------------|----------------------------------|-----------------|--------------|----------------|--------------|----------------|--------------|----------------|--------------|
|                 | Time 1 year 3 year 5 year        |                 |              |                |              |                |              |                |              |
| Unmatched group | Surgery(%, 95%CI) 5.37 (3.63-7.90) | 2.79 (1.59-4.92) | 12.04 (9.18-15.71) | 9.7 (6.93-13.57) | 16.87 (13.22-21.40) | 14.29 (10.54-19.38) |
|                 | ET(%, 95%CI) 2.07 (.64-4.47) | 3.65 (1.90-7.02) | 5.56 (2.79-9.56) | 14.73 (10.1-21.49) | 11.08 (6.28-18.05) | 25.71 (18.55-35.64) |
| Matched group   | Surgery(%, 95%CI) 2.88 (1.30-6.42) | 2.88 (1.30-6.42) | 10.31 (6.76-17.28) | 13.06 (8.54-19.9) | 17.61 (12.83-28.87) | 19.33 (13.09-28.53) |
|                 | ET (% 95% CI) 2.04 (.76-5.43) | 3.90 (1.95-7.79) | 6.38 (3.38-12.05) | 14.98 (9.96-22.52) | 12.16 (6.79-21.78) | 25.05 (17.46-35.92) |
Figure 3. The cumulative curves for the long-term cancer-specific death in surgery vs Endoscopic treatment (ET) group before (A) and after (B) PSM, in T1a vs T1b-stage group before (C) and after (D) PSM, and in age≥65 y vs age<65 y group before (E) and after (F) PSM.

| Subgroup                      | ET Median (mos) | Surgery Median (mos) | SHR (95% CI) | p-value |
|-------------------------------|----------------|----------------------|--------------|---------|
| All patients                  | NR             | NR                   | 0.91 (0.68-1.22) | 0.53    |
| Age at diagnosis (y)          |                |                      |              |         |
| <65                           | NR             | NR                   | 2.05 (0.60-7.00) | 0.25    |
| ≥65                           | NR             | NR                   | 2.16 (1.20-3.91) | 0.01*   |
| Sex                           |                |                      |              |         |
| Female                        | NR             | NR                   | 1.18 (0.36-3.81) | 0.79    |
| Male                          | NR             | NR                   | 2.14 (1.18-1.29) | 0.01*   |
| Race                          |                |                      |              |         |
| Non-Hispanic                  | NR             | NR                   | 1.79 (1.05-3.06) | 0.03*   |
| Hispanic                      | -              | -                    |              |         |
| Tumor Size                    |                |                      |              |         |
| <3cm                          | NR             | NR                   | 1.57 (0.91-2.72) | 0.11    |
| ≥3cm                          | -              | -                    |              |         |
| Histology grade               |                |                      |              |         |
| Well/ Moderately              | NR             | NR                   | 1.73 (0.93-3.24) | 0.09    |
| Poorly/Undifferentiated       | NR             | NR                   | 2.25 (0.78-6.46) | 0.13    |
| T stage                       |                |                      |              |         |
| T1a                           | NR             | NR                   | 2.54 (1.07-6.04) | 0.03*   |
| T1b                           | NR             | NR                   | 1.06 (0.54-2.08) | 0.87    |

Figure 4. Forest plot of the long-term cancer-specific death in different subgroups.
were compared using the Fine-Gray test. Univariate and multivariate competing regression was performed to identify significant prognostic factors using the subdistribution hazard ratio (SHR). The reported statistical significance levels were two-sided, and $P \leq .05$ was deemed statistically significant.

**Results**

**Baseline Characteristics**

Based on the established inclusion and exclusion criteria, 725 patients were enrolled, among whom 462 underwent surgery and 263 received ET (Figure 1). The number of patients receiving ET increased by 15.6% annually (95% CI: -11.4-42.6%) from 2010 to 2018. Conversely, we detected a decreasing trend in the number of patients undergoing surgery (annual percent change: -12.5%, 95% CI: -28.5-3.5%) during the same period. Figure 2 shows the distribution of patients who underwent surgery or ET from 2010 to 2018.

Considering the ET group, the median age was 71 years (interquartile range [IQR], 55-87 years), comprising 74.5% males, and 6.8% Hispanic subjects. In the surgery group, the median age was 67 years (IQR, 53-81 years), with 78.1% males, and 7.4% Hispanic subjects. The proportions of patients $>65$ years of age was higher in the ET group than that in the surgery group (72.2% vs. 61.0%, $P<.01$). Moreover, the ET groups comprised a greater number of patients in the T1a stage than the surgery group (70.3% vs. 38.5%, $P < .01$).
PSM

Given the significant differences in variables between surgery and ET groups (including age, tumor size, differentiation, histological type, and invasion depth), we performed a PSM algorithm by adjusting these confounding factors. The matching method generated 2 balanced groups, each comprising 219 patients. After PSM, each examined variable exhibited no statistical difference between the surgery and ET groups. Table 1 presents the baseline characteristics of patients before and after matching.

Survival Analysis

Table 2 summarizes the survival data of CSD and OCD in ET and surgery groups before and after matching. Figure 3 shows the cumulative curves for long-term cancer-specific survival before and after PSM. Before PSM, the 5 year cumulative incidences of CSD was significantly higher in the surgery group than that in the ET group (16.87% vs 11.08%, Fine-Gray test $P = .01$). Patients in the ET group exhibited a significantly higher 5 year incidence of OCD than those in the surgery group (25.71% vs. 14.29%, Fine-Gray test $P < .01$).

Following subgroup analysis, surgery presented a higher CSD risk than ET for age $\geq 65$, males, non-Hispanic, and T1 stage subgroups, respectively (Figure 4). Based on multivariate competing regression, age was identified as an independent prognostic factor for the CSD (SHR 2.01, 95%CI 1.19-3.40, $P < .01$), whereas the choice of ET or surgery was not a significant prognostic factor of survival (SHR 1.54 95%CI 0.86-2.76, $P = .15$). Furthermore, age $\geq 65$ (SHR 3.19, 95%CI 1.89-5.39, $P < .01$) and choice of ET (SHR 1.56, 95%CI 1.89-5.39, $P < .01$) were significantly associated with high OCD.

Table 4 presents the distribution of patients who underwent surgical interventions or ET. We found that CSD did not differ significantly across different surgical interventions (Fine-Gray test $P = .74$) or ET (Fine-Gray test $P = .11$) (Figure 5(A), 5(B)). In the T1b subgroup (n = 362), the risk of CSD did not differ significantly between the ET and surgery groups (Fine-Gray test $P = .87$). However, considering the age $\geq 65$ subgroups, patients in the ET group showed a significantly lower 5 year incidence of CSD than those in surgery groups (15.0% vs. 20.9%, Fine-Gray test $P < .01$) (Figure 5(C), 5(D)).

After PSM, the Fine-Gray test revealed no significant difference in the 5 year cumulative incidence of CSD between surgery and ET cohorts (17.61% vs 12.16%, $P = .14$). In multivariate analysis, the incidence of CSD was higher among patients with aged $\geq 65$ years (SHR 2.29, 95%CI 0.99-5.33, $P = .05$) and T1b-stage (SHR 1.92, 95%CI 1.03-3.57, $P = .04$), whereas the treatment method (surgery or ET) was not significantly associated with cancer survival (SHR 1.51, 95% credible interval (CI) .81-2.81, $P = .20$) (Table 4). Moreover, patients who underwent ET presented a considerably higher OCD than those who underwent surgery (19.33% vs. 25.05%, $P < .01$).

| Variables | Univariate analysis | Multivariable analysis |
|-----------|---------------------|------------------------|
| Age at diagnosis (years) | | |
| <65 | Reference | |
| $\geq 65$ | 2.84 (1.27-6.35) | .01* |
| Sex | | |
| Female | Reference | |
| Male | 1.47 (.66-3.26) | .35 |
| Race | | |
| Non-hispanic | Reference | |
| Hispanic | .83 (.20-3.43) | .79 |
| Tumor size (cm) | | |
| <3 | Reference | |
| $\geq 3$ | 2.95 (1.57-5.52) | <.01* |
| Histology grade | | |
| Well/Moderately | Reference | |
| Poorly/Undifferentiated | 1.77 (.92-3.42) | .09 |
| T Stage | | |
| T1a | Reference | |
| T1b | 2.22 (1.27-4.01) | <.01* |
| Therapy | | |
| Endoscopic treatment | Reference | |
| Surgery | 1.58 (85.297) | .15 |

Note: Each *statistical significance was considered as $P \leq .05$. 

Table 3. Univariate and Multivariate Analyses of SEGC Cancer-Specific Survival.
surgery in multivariate analysis, it failed to achieve a statistical significance (SHR 1.43, 95% CI 0.44-1.11, \( P = .13 \)) (Table 5).

**Discussion**

Given the unique location on the boundary between the esophagus and the stomach, no consensus has been reached regarding an optimal therapeutic strategy for EGJ adenocarcinomas.\(^{22}\) ET and surgery are 2 therapeutic options available for patients with Siewert Type II T1M0N0 AEG. In the present study, we documented a decreasing trend of surgical resection and an increasing trend for ET among patients undergoing treatment from 2010 to 2018. These findings indicate that ET has been increasingly recognized as an effective strategy for early-stage AEG. However, few studies assessing Western populations have provided survival data for these patients post-treatment. To address this gap in knowledge, our study compared the long-term prognosis between ET and surgery using the SEER database. To reach a more precise statistical comparison: (1) we applied the PSM algorithm to decrease confounding factors such as age, tumor size, differentiation, histological type, and tumor invasion; (2) we applied the competing-risk regression analysis, which may be more precise by providing an alternative to Cox regression in the presence of 1 or more competing survival outcomes, such as tumor-specific mortality and other causes of mortality.\(^{23}\)

---

**Table 4.** Distribution of Patients Receiving Surgery Or Endoscopic Treatment.

| Treatment       | The Detail of Method                  | No. of Patients | Survival Rate, % |
|-----------------|---------------------------------------|-----------------|------------------|
| Surgery (n = 462) | Partial or subtotal gastrectomy        | 307             | 72.3             |
|                 | Near-total or total gastrectomy        | 86              | 72.1             |
|                 | Gastrectomy, NOS                        | 69              | 71.1             |
| ER (n = 263)    | Local tumor destruction                 | 2               | 50.0             |
|                 | Electrocautery/fulguration              | 2               | 50.0             |
|                 | Local tumor excision                    | 19              | 68.4             |
|                 | Polypectomy                             | 149             | 73.8             |
|                 | Excisional biopsy                       | 66              | 78.8             |
|                 | NOS                                    | 66              | 78.8             |
|                 | Local destruction and excision          | 27              | 77.8             |

**Table 5.** Univariate and Multivariate Analyses of SEGC Other Cause of Death.

| Variables                          | Univariate Analysis | Multivariable Analysis |
|------------------------------------|---------------------|------------------------|
|                                    | SHR, (95% CI)       | \( P \)               | SHR, (95% CI)       | \( P \)               |
| Age at diagnosis (years)           |                     |                       |                     |                       |
| <65                                | Reference           | 4.40 (2.10-9.21)      | <.01*               | 3.96 (1.89-8.30)      | <.01*                 |
| ≥ 65                               | Reference           | .72                   | .59                 | .63 (1.19-2.14)       | .46                   |
| Sex                                |                     |                       |                     |                       |
| Female                             | Reference           | 1.10 (.64-1.91)       | .28                 | 1.08 (.79-1.49)       | .62                   |
| Male                               |                     |                       |                     |                       |
| Race                               |                     |                       |                     |                       |
| Non-hispanic                       | Reference           | .46 (.12-1.74)        | .25                 | .63 (.19-2.14)        | .46                   |
| Hispanic                           |                     |                       |                     |                       |
| Tumor size (cm)                    |                     |                       |                     |                       |
| <3                                 | Reference           | 1.90 (.99-3.63)       | .05*                | 1.65 (.82-3.31)       | .16                   |
| ≥ 3                                | Reference           | 1.19 (.87-1.64)       | 1.23 (.77-1.96)     | .39                   | 1.09 (.68-1.73)       | .73                   |
| Histology grade                    |                     |                       |                     |                       |
| Well/Moderately                    | Reference           | 1.19 (.87-1.64)       | .28                 | 1.08 (.79-1.49)       | .62                   |
| Poorly/Undifferentiated            | Reference           | 1.23 (.77-1.96)       | .39                 | 1.09 (.68-1.73)       | .73                   |
| T Stage                            |                     |                       |                     |                       |
| T1a                                 | Reference           | 1.23 (.77-1.96)       | .39                 | 1.09 (.68-1.73)       | .73                   |
| T1b                                 | Reference           | 1.09 (.68-1.73)       | .73                 | .70 (.44-1.11)        | .13                   |
| Therapy                            |                     |                       |                     |                       |
| Endoscopic treatment               | Reference           | .70 (.44-1.11)        | .13                 | .70 (.44-1.11)        | .13                   |
| Surgery                            | Reference           | .69 (.44-1.09)        | .12                 | .70 (.44-1.11)        | .13                   |

Note: *statistical significance was considered as \( P \leq .05 \).
The standard Cox model is a well-established methodology for calculating survival outcomes. Completing-risk regression is an alternate statistical method for handling survival data and has been reported in several high-impact journals. Wolbers et al have reported that the standard Cox model overestimated the 10 year risk of coronary heart disease when compared with the estimate from the competing-risk regression. This finding could be attributed to the results of the traditional Cox survival function, with estimates of incidence biased upward, regardless of whether the competing events are independent of 1 another. It should be noted that several clinical survival studies lacking competing events. For instance, in our study, the primary outcome in the present study was time to death due to AEG. Death attributable to a non-cancer cause is considered a competing event. A subject who dies of a disease of other systems is no longer at risk of death attributable to cancer. Accordingly, the competing-risk model has greater relevance than Cox regression in analyzing survival data in our study, given the presence of competing survival events.

The most important findings of the present study were as follows: (1) there was no statistically significant difference in the long-term survival of patients undergoing surgery or ET; (2) the surgery group had a higher risk of death than the ET group, considering patients ≥65 years old or with T1a stage tumor; (3) Age and tumor invasion could be independent prognostic factors for patients with Siewert Type II early AEG. (4) In patients aged ≥65 years or with T1b tumor, ET could be a primary strategy, affording a comparable survival rate to surgical treatment.

Surgery is the primary treatment strategy for gastric cancer and AEG owing to its advantages in terms of complete tumor resection and lymph node dissection. However, surgery is well-known to be associated with considerable postoperative morbidity and mortality. Compared with surgical resection, ET is a minimally invasive procedure with low morbidity and mortality and improved quality of life owing to organ preservation. Typically, the indications for ET include mucosal (T1a) and submucosal (T1b) cancer without lymph node metastasis. In the present study, the enrolled patients were node-negative T1 stage within the indication of ET. Our results detected no significant difference in the long-term survival outcome between surgery and ET among Western populations, consistent with the findings previously reported in Asian countries. Moreover, the CSD rates in ET or surgery groups did not significantly differ considering patients with submucosal (T1b) cancer. Accordingly, ET can be considered a primary treatment strategy for T1b tumors, given its minimally invasive nature and capacity to afford an improved quality of life. The ET choice may be more relevant in patients older than 65 years, given the significantly high CSD detected in the surgery group. Our study emphasized the application of ET in submucosal (T1b) cancer, as surgery remains the primary treatment strategy recommended by most Western guidelines. However, our results revealed that ET could afford a comparable survival rate to surgical treatment in patients with T1b tumors. Thus, we propose utilizing ET as a primary method in patients with T1b tumors. Although comparisons performed before PSM showed a higher CSD in the surgery group than that in the ET group, this could be attributed to confounding bias, given the presence of different pathological characteristics between the 2 groups. After adjusting confounding bias, no statistical difference was detected.

Compared with the survival data (more than 90%) reported in previous Asian studies, the 5 year disease-specific survival was reduced in both surgery (87.8%) and ET (82.4%) cohorts in the present study. This finding could be attributed to 2 possible factors. Firstly, the previously reported Asian studies are single-center studies with relatively small sample sizes, and their survival data includes all Siewert types of early-stage cancer. Our study specifically investigated the survival outcome in Siewert II type cancer of AEG. In addition, Asian studies mainly performed endoscopic submucosal dissection (ESD) as the primary endoscopic resection method. However, ET includes both local tumor excisions and destruction (photodynamic therapy, cryosurgery, or laser) in the SEER database. Furthermore, local tumor excisions were not described in detail to differentiate whether patients received exact endoscopic mucosal resection or ESD. Thus, survival data cannot be precisely compared between Asian and Western populations owing to different categories of ET. Secondly, Americans and Asians are 2 distinct ethnic groups, and different genetic factors may underlie the incidence of AEG cancers in these groups. Thus, the survival data may differ. Furthermore, we found that patients who underwent ET had a considerably higher incidence of OCD than those who received surgery. Patients ≥65 years had a significantly high risk of OCD. This may be attributed to the higher incidence of obesity, diabetes, and cardiovascular diseases among Western populations than among Asian populations.

To the best of our knowledge, few studies have investigated the long-term prognosis of AEG in Asian countries. Feng et al have recently reported that adjuvant chemotherapy, the ratio of positive to negative lymph nodes, intraoperative blood transfusion, tumor size, perineural invasion, serum CEA, and duration of hospital stay post-surgery could be independent risk factors for survival in all stages of Siewert Type II AEG adenocarcinoma. Guo et al have revealed that the age, tumor grade, T stage, and N stage are independently associated with the survival prognosis of AEG cancer with no distant metastasis. However, no report has independently investigated the long-term prognosis among Western populations with early-stage (T1) cancer. Our study identified age and tumor invasion as 2 independent prognostic factors in T1M0N0 AEG adenocarcinoma. These findings emphasized the role of age and tumor invasion in evaluating AEG in all stages.

Our study has some limitations that need to be addressed. Firstly, this was a retrospective cohort study using the SEER database. Variable selection bias may exist as some detailed clinicopathological factors were not accessible, such as margin, lymphovascular invasion, complete resection rate, and local or distal metastasis. Secondly, given the limitations of the SEER database, we were unable to access the survival data in Siewert type I and III of AEG adenocarcinoma. Thus, additional studies are needed to determine whether long-term
survival outcomes differ among different Siewert types of AEG adenocarcinomas. However, the strengths of the present study should be noted. We, for the first time, independently compared the long-term prognosis of surgery and ET in patients with Siewert Type II pT1N0M0 AEG among the United States population. Secondly, the survival data in our study may be more precise owing to the application of the PSM methodology and competing-risk regression.

**Conclusion**

Long-term survival outcomes did not differ significantly between patients who received surgery or ET in the U.S. population. For Siewert Type II pT1N0M0 AEG adenocarcinoma, ET may be primarily considered in patients older than 65 years or those with sub-mucosal (T1b-stage) invasion.

**Author Contribution**

Han Chen: study concept and design, analysis and interpretation of data; drafting of the manuscript, authorship; Xin Yu: study concept and design, analysis and interpretation of data, authorship. Ruoyun Yang: data extraction, design and order the figures and tables, assessment of study quality, authorship. Shuo Li: data extraction, design and order the figures and tables, authorship. Guoxin Zhang: design and order the figures and tables, assessment of study quality. Xinmin Si and Xiaoying Zhou: critical revision of the manuscript for important intellectual content; obtain funding; study supervision, authorship.

**Declaration of Conflicting Interests**

The authors(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The raw data and programming code could be assessed by contracting the corresponding author. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the National Natural Science Foundation of China (No. 82100594), Jiangsu province Hospital (the First Affiliated Hospital with Nanjing Medical University) Clinical Capacity Enhancement Project (JSPH-MC-2022-29) and Postgraduate Research and Practice Innovation Program of Jiangsu Province (SICX22_0697). All the authors approved the submitted version of the manuscript.

**Ethnic Approval**

This study was conducted in accordance with the Declaration of Helsinki.

**Informed Consent**

Institutional review board approval and informed consent were not required in the current study because SEER research data are publicly available and all patients data are de-identified.

**ORCID iD**

Xiaoying Zhou  https://orcid.org/0000-0002-6529-0243

**References**

1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654-2664.
2. Dubecz A, Solymosi N, Stadhuber RJ, et al. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century? a SEER database analysis. J Gastrointest Surg 2013. doi:10.1007/s11605-013-2345-8. in press.
3. Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635-648.
4. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? Semin Oncol. 2004;31(4):444-449.
5. Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophago-gastric junction. Scand J Gastro. 2006;95:260-269.
6. Zhu K, Xu Y, Fu J, et al. Proximal gastrectomy versus total gastrectomy for siewert type II adenocarcinoma of the esophagogastric junction: A comprehensive analysis of data from the SEER registry. Dis Markers. 2019. 2019(31):9637972.
7. Chen L, Tang K, Wang S, Chen D, Ding K. Predictors of lymph node metastasis in siewert type II T1 adenocarcinoma of the esophagogastric junction: A population-based study. Cancer Control 2021;28.
8. Kusano C, Gotoda T, Khor CJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23(11):1662-1665.
9. Sugita S, Kinoshita T, Kuwata T, et al. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc. 2021;35(1):340-348.
10. Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(7):855-883.
11. Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer. Cancer. 2019;15125(12):1990-2001.
12. Fang FH, Shen L, Li J, et al. The Chinese society of clinical oncology (esco): Clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun. 2019;1839(1):10.
13. Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer (second edition). Dig Endosc. 2021;33(1):4-20.
14. Meng FS, Zhang ZH, Wang YM, Lu L, Zhu IZ, Ji F. Comparison of endoscopic resection and gastrectomy for the treatment of early gastric cancer: a meta-analysis. Surg Endosc. 2016;30(9):3673-3683.
15. Kim HJ, Chung H, Shin SK, et al. Comparison of long-term clinical outcomes between endoscopic and surgical resection for early-stage adenocarcinoma of the esophagogastric junction. Surg Endosc. 2018;32(8):3540-3547.
16. Gong EJ, Kim do H, So H, et al. Clinical outcomes of endoscopic submucosal dissection for adenocarcinoma of the esophagogastric junction. *Dig Dis Sci*. 2016;61(9):2666-2673.

17. Feng Y, Jiang Y, Zhao Q, Liu J, Zhang H, Chen Q. Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: A seven-year study. *BMC Surg*. 2020;20(1):302.

18. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. *CA Cancer J Clin* 2017;67(2):93-99.

19. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. *Multivariate Behav Res*. 2011;46(3):399-424.

20. Latouche A, Porcher R. Sample size calculations in the presence of competing risks. *Stat Med*. 2007;26(30):5370-5380.

21. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. *Bone Marrow Transplant*. 2007;40(4):381-387.

22. Mariette C, Piessen G, Briez N, Gronnier C, Triboulet JP. Oesophagogastric junction adenocarcinoma: which therapeutic approach? *Lancet Oncol*. 2011;12(3):296-305.

23. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation*. 2016;133(6):601-609.

24. Koller MT, Raatz H, Steyerberg EW, Wolbers M. Competing risks and the clinical community: irrelevance or ignorance? *Stat Med*. 2012;31:1089-1097.

25. Wolbers M, Koller MT, Witteman JC, Steyerberg EW. Prognostic models with competing risks: methods and application to coronary risk prediction. *Epidemiology*. 2009;20:555-561.

26. Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: Results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. *Ann Surg*. 2000;232(3):353-361.

27. Ryu SJ, Kim BW, Kim BG, et al. Endoscopic submucosal dissection versus surgical resection for early gastric cancer: A retrospective multicenter study on immediate and long-term outcome over 5 years. *Surg Endosc*. 2016;30(12):5283-5289.

28. Yoshinaga S, Gotoda T, Kusano C, et al. Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. *Gastrointest Endosc*. 2008;67(2):202-209.

29. Park CH, Kim EH, Kim HY, Roh YH, Lee YC. Clinical outcomes of endoscopic submucosal dissection for early stage esophagogastric junction cancer: A systematic review and meta-analysis. *Dig Liver Dis*. 2015;47(1):37-44.

30. Gong EJ, Kim DH, Ahn JY, et al. Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma. *Gastric Cancer*. 2017;20(suppl 1):84-91.

31. Guo Q, Peng Y, Yang H, Guo J. Prognostic nomogram for postoperative patients with gastroesophageal junction cancer of no distant metastasis. *Front Oncol*. 2021;11:643261.